Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q4 2019 Earnings Snapshot

— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.

— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.

— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.

— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.

— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.

— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.

— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.

— SNY stock was up about 4% in the pre-market trading session.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Kin Insurance’s strategy is focused on growing in catastrophe-exposed states: CEO Sean Harper

Kin Insurance is a leading insurance technology company specialized in high-risk residential areas. The direct-to-consumer business model and use of advanced technology allow the company to offer affordable pricing without

Infographic: Key highlights from Best Buy (BBY) Q1 2023 earnings results

Best Buy Co., Inc. (NYSE: BBY) reported first quarter 2023 earnings results today. Enterprise revenue dropped to $10.6 billion from $11.6 billion in the year-ago period. Comparable sales were down

AutoZone (AZO) Q3 Earnings: Key financials and quarterly highlights

AutoZone, Inc. (NYSE: AZO) reported third quarter 2022 earnings results today. Net sales increased 5.9% year-over-year to $3.9 billion. Domestic same-store sales increased 2.6%. Net income decreased 0.6% to $592.6 million, while

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top